文献速递骨质疏松与代谢性骨病

原发性甲状旁腺功能亢进症患者停用地舒单抗后出现高钙血症:一例病例报告及文献综述

Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review.
PubMed 文献 · Osteoporos Int · 2020-10-15

一例86岁女性骨质疏松患者在连续3年每6个月皮下注射地舒单抗60 mg期间已知患有原发性甲状旁腺功能亢进症,末次注射9个月后因健康状况恶化住院,发现严重高钙血症(血钙3.35 mmol/l)及多发新发自发性椎体骨折,骨转换标志物显著升高提示反跳效应;再次注射地舒单抗60 mg后血钙迅速下降、骨转换标志物大幅降低,微创甲状旁腺切除术最终使甲状旁腺功能亢进症及高钙血症得到确定性缓解。本文提示停用地舒单抗所致高钙血症在合并原发性甲状旁腺功能亢进症等其他高钙血症病因时可变得严重。

要点

  • 停用地舒单抗可伴骨吸收快速增加及骨密度下降,并可能出现反跳相关高钙血症。
  • 本例86岁女性在末次地舒单抗注射9个月后出现严重高钙血症(血钙3.35 mmol/l)及多发新发自发性椎体骨折。
  • 再次注射地舒单抗60 mg后血钙迅速下降、骨转换标志物大幅降低,微创甲状旁腺切除术使高钙血症得到确定性缓解。

核心结论

  • 本病例提示高钙血症可为停用地舒单抗的副作用,当存在原发性甲状旁腺功能亢进症等其他高钙血症病因时可变得严重。

研究设计与样本

  • 病例报告及文献综述:一例86岁女性骨质疏松患者接受地舒单抗60 mg皮下注射每6个月一次共3年,已知患有原发性甲状旁腺功能亢进症。

主要发现

  • 末次地舒单抗注射9个月后因健康状况恶化住院,临床评估显示严重高钙血症(血钙3.35 mmol/l),骨转换标志物极高提示地舒单抗停药反跳效应,X线显示多发新发自发性椎体骨折。
  • 再次注射地舒单抗60 mg后血钙迅速下降、骨转换标志物大幅降低。
  • 微创甲状旁腺切除术使甲状旁腺功能亢进症及高钙血症得到确定性缓解。
  • 在地舒单抗药效结束时,血清白蛋白校正钙为2.82 mmol/l(参考值2.15-2.5 mmol/l)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Denosumab discontinuation is associated with a rapid increase in bone resorption and a decrease in bone mineral density. Spontaneous vertebral fractures may occur as a side effect of the rebound of bone resorption. Cases of rebound-linked hypercalcemia have also been described, moderate in women with osteoporosis and breast cancer and severe in children receiving oncological doses of denosumab. We report the case of an adult woman with primary hyperparathyroidism and moderate hypercalcemia, treated with denosumab for osteoporosis, who developed severe hypercalcemia and spontaneous vertebral fractures (SVFs) after denosumab discontinuation. An 86-year-old woman with densitometric osteoporosis was treated for 3 years with 60 mg of subcutaneous denosumab every 6 months. She was known to have primary hyperparathyroidism, with a serum albumin-corrected calcium of 2.82 mmol/l (NV 2.15-2.5) at the end of denosumab effect. Nine months after the last denosumab injection, she was hospitalized due to worsening overall health. Clinical evaluation revealed severe hypercalcemia (calcium 3.35 mmol/l). Very high values of bone turnover markers (BTMs) suggested a rebound effect due to denosumab discontinuation. An X-ray showed multiple new SVFs. After injection of denosumab 60 mg, serum calcium rapidly decreased and BTMs were dramatically reduced. A surgical approach by minimally invasive parathyroidectomy allowed for definite resolution of hyperparathyroidism and hypercalcemia. This case suggests that hypercalcemia can be a side consequence of denosumab discontinuation, which can become severe when other causes of hypercalcemia, such as primary hyperparathyroidism, are present.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Camponovo C, Aubry-Rozier B, Lamy O, et al. Hypercalcemia upon denosumab withdrawal in primary hyperparathyroidism: a case report and literature review. Osteoporos Int. 2020. PMID: 33057735. doi:10.1007/s00198-020-05676-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。